decitabine + panobinostat

Combination of the DNA hypomethylating agent decitabine with the pan‑histone deacetylase inhibitor panobinostat (LBH589) designed for dual epigenetic modulation in cancer. Decitabine incorporates into DNA and inhibits DNA methyltransferases, leading to DNA hypomethylation and gene re-expression. Panobinostat inhibits class I, II, and IV HDACs, increasing histone acetylation and altering transcription; it can deplete DNMT1 and EZH2 and synergize with decitabine to de-repress tumor suppressors and reduce leukemic cell survival. Investigated in early-phase trials for myelodysplastic syndromes, acute myeloid leukemia, and breast cancer, and in preclinical/clinical exploratory settings for solid tumors including melanoma, typically as a sequential or concurrent epigenetic therapy regimen.[1][5][7][9][10][2]

Brand names

Farydak

Other names

decitabine + LBH-589decitabine + LBH 589decitabine + pan-deacetylase inhibitordecitabine + HDAC inhibitor panobinostat